Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674532 | 0.90 | MCHR1 (0.39) | MCHR1HSD11B1ROCK2TRIM24TRIM33 | |
| SCHEMBL4518383 | 0.90 | MCHR1 (0.39) | MCHR1HSD11B1ROCK2TRIM24TRIM33 | |
| SCHEMBL13675620 | 0.88 | HSD11B1 (0.39) | MCHR1HSD11B1ROCK2 | |
| SCHEMBL13675467 | 0.85 | HSD11B1 (0.39) | MCHR1HSD11B1ROCK2 | |
| SCHEMBL13675549 | 0.85 | HSD11B1 (0.41) | HSD11B1ROCK2 | |
| SCHEMBL13675523 | 0.83 | DPP4 (0.37) | HSD11B1 | |
| SCHEMBL13675465 | 0.81 | AVPR1A (0.42) | MCHR1 | |
| SCHEMBL13674533 | 0.81 | ACVRL1 (0.36) | MCHR1HSD11B1ROCK2 | |
| SCHEMBL4516016 | 0.81 | ACVRL1 (0.36) | MCHR1HSD11B1ROCK2 | |
| SCHEMBL13675572 | 0.80 | KMT2A (0.35) | HSD11B1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | MCHR1 2133/4885HSD11B1 1/4885ROCK2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.